Payload Logo

Fake weight loss drugs, and Novo Nordisk's CEO will face Bernie Sanders: Pharma news roundup

By Bruce Gil
Published

The World Health Organization issued a warning regarding fake batches of Ozempic in Europe and the U.S. the same day Eli Lilly filed lawsuits against companies selling counterfeit versions of its weight loss drug Zepbound. Gilead’s HIV prevention injection was found to work with 100% efficacy in a clinical trial. Novo Nordisk CEO Lars Fruergaard Jørgensen has agreed to voluntarily testify in September before the Senate’s health committee.

Check out those stories and more pharmaceutical news highlights from this week.

Look out for fake Ozempic in the U.S. and Europe, WHO warns

The World Health Organization (WHO) issued a global alert Wednesday warning the public about fake batches of Ozempic across Europe and the Americas. 

Read More

Gilead says its HIV prevention shot was 100% effective in a clinical trial

Gilead announced that its twice-yearly injection, lenacapavir, worked with 100% efficacy at preventing HIV infections in a late-stage clinical trial. 

Read More

Ozempic and other weight loss drugs could help alcoholics, too

The evidence is starting to pile up that Ozempic and other GLP-1 medications could help people with substance abuse disorders. Researchers from the University of North Carolina found that people with alcohol use disorder drank less after taking semaglutide, the active ingredient in Novo Nordisk’s Ozempic, compared with with people who took a placebo. 

Read More

Eli Lilly is cracking down on knock-off versions of its popular weight loss drug Zepbound

Eli Lilly said Thursday that it is taking legal action against six entities for selling unapproved versions of its popular weight loss and diabetes medication tirzepatide — the generic name of Mounjaro and Zepbound. 

Read More

Drug names: Branding a molecule

Stelara, Comirnaty, Sronyx — why are drug names often so strange? It’s actually primarily due to safety. Settling on a name can take a drug manufacturer up to four years and involves several regulatory agencies.

Read More

Tech founder claims he successfully slowed down his aging by editing his DNA

The tech entrepreneur who once had his son’s plasma infused with his blood in an attempt to extend his own life now claims that he successfully slowed the aging process by undergoing an untested DNA editing procedure on a Honduran island. 

Read More

Bernie Sanders will grill Novo Nordisk’s CEO over Ozempic and Wegovy prices

Novo Nordisk CEO Lars Fruergaard Jørgensen has agreed to voluntarily testify in September before the Senate’s health committee to address the pharma giant’s high prices for its diabetes and weight loss drugs in the U.S. 

Read More

Ozempic is now boosting sales for smaller-sized clothes, fashion executives say

In another ripple effect on the economy, Ozempic and other weight loss drugs are boosting sales of smaller-sized clothes. 

Read More

Food companies worried about weight loss drugs can just make healthier food, Eli Lilly CEO says

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, says that food, diet, and fitness companies have called him for advice regarding the growing popularity of the company’s diabetes and weight loss drugs. 

Read More

Eli Lilly wants to replace Zepbound with an even stronger weight loss drug

Skyrocketing sales of tirzepatide — the active ingredient in Mounjaro and Zepbound — transformed Eli Lilly into the most valuable pharmaceutical company in the world, but CEO David Ricks says the company is already looking ahead to a successor for the blockbuster drug. 

Read More

📬 Sign up for the Daily Brief

Our free, fast and fun briefing on the global economy, delivered every weekday morning.